Revising the Role of the Androgen Receptor in Breast Cancer

    Flavia Marialucia Fioretti, Ailsa Sita-Lumsden, Charlotte Bevan, Greg Brooke
    Image of study
    TLDR The document concludes that targeting the androgen receptor may be a promising breast cancer treatment, especially for certain types.
    The document from 2014 reviews the role of the androgen receptor (AR) in breast cancer (BC), suggesting that AR positivity is associated with a better prognosis in ER-positive BC and may serve as a therapeutic target, particularly in a subset of triple-negative BCs (TNBCs) known as molecular apocrine. It discusses the potential of AR pathway activation in BC treatment, with clinical trials investigating antiandrogen therapies like bicalutamide and abiraterone acetate. The review also notes the prognostic value of AR, the heterogeneity of BC subtypes, and the importance of molecular profiling in managing BC. It concludes that targeting AR could be a promising strategy for BC patients, especially those with molecular apocrine disease, and highlights the need for further clinical trials to explore AR-targeted therapies.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results

    Related Community Posts Join

    6 / 1000+ results

    Related Research

    1 / 1 results